Baseline platelet counts and derived inflammatory biomarkers: prognostic relevance in metastatic melanoma patients receiving Endostar plus dacarbazine and cisplatin

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Tripp MK, Watson M, Balk SJ, Swetter SM, Gershenwald JE. State of the science on prevention and screening to reduce melanoma incidence and mortality: the time is now. CA Cancer J Clin. 2016;66(6):460–480. doi:10.3322/caac.2135227232110
   PubMed Web of Science ®Google Scholar
• Zhu Z, Liu W, Gotlieb V. The rapidly evolving therapies for advanced melanoma–towards immunotherapy, molecular targeted therapy, and beyond. Crit Rev Oncol Hematol. 2016;99:91–99. doi:10.1016/j.critrevonc.2015.12.00226708040
   PubMed Web of Science ®Google Scholar
• Lindsay CR, Spiliopoulou P, Waterston A. Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. Ther Adv Med Oncol. 2015;7(2):107–121. doi:10.1177/175883401456661925755683
   PubMed Web of Science ®Google Scholar
• Ekwueme DU, Guy GP, Li C, Rim SH, Parelkar P, Chen SC. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity–United States, 2000 to 2006. J Am Acad Dermatol. 2011;65(5):S131–S133. doi:10.1016/j.jaad.2011.04.036
   Web of Science ®Google Scholar
• Limaverde-Sousa G, Sternberg C, Ferreira CG. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents. Cancer Treat Rev. 2014;40(4):548–557. doi:10.1016/j.ctrv.2013.11.00924360358
   PubMed Web of Science ®Google Scholar
• Zhu H, Yang X, Ding Y, et al. Recombinant human endostatin enhances the radioresponse in esophageal squamous cell carcinoma by normalizing tumor vasculature and reducing hypoxia. Sci Rep. 2015;5:14503. 26412785
   PubMed Web of Science ®Google Scholar
• Li N, Zheng D, Wei X, Jin Z, Zhang C, Li K. Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model. J Cancer Res Clin Oncol. 2012;138(7):1131–1144. doi:10.1007/s00432-012-1189-z22402599
   PubMed Web of Science ®Google Scholar
• Li XQ, Shang BY, Wang DC, Zhang SH, Wu SY, Zhen YS. Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth. Cancer Lett. 2011;301(2):212–220. doi:10.1016/j.canlet.2010.12.00421216091
   PubMed Web of Science ®Google Scholar
• Cui C, Mao L, Chi Z, et al. A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Mol Ther. 2013;21(7):1456–1463. doi:10.1038/mt.2013.7923670576
   PubMed Web of Science ®Google Scholar
• Chen J, Yao Q, Huang M, et al. A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first-line therapy for patients with breast cancer (CBCRT01). Int J Cancer. 2018;142(10):2130–2138. doi:10.1002/ijc.3121729238974
   PubMed Web of Science ®Google Scholar
• An J, Lv W. Endostar (rh-endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer: a meta-analysis. Thorac Cancer. 2018;9(5):606–612. doi:10.1111/1759-7714.1262629575575
   PubMed Web of Science ®Google Scholar
• Jin T, Jiang F, Jin Q, Piao Y, Chen X. Endostar combined with gemcitabine and cisplatin chemotherapy for patients with metastatic nasopharyngeal carcinoma: an update. Transl Oncol. 2018;11(2):286–291. doi:10.1016/j.tranon.2018.01.00229413761
   PubMed Web of Science ®Google Scholar
• Ferrucci PF, Ascierto PA, Pigozzo J, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2016;27(4):732–738. doi:10.1093/annonc/mdw01626802161
   PubMed Web of Science ®Google Scholar
• Teterycz P, Jagodzinska-Mucha P, Cybulska-Stopa B, et al. High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors. Melanoma Res. 2018;28(5):435–441. doi:10.1097/CMR.000000000000046129782381
   PubMed Web of Science ®Google Scholar
• Zhan H, Ma J, Jian Q. Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: a meta-analysis. Clin Chim Acta. 2018;484:136–140. doi:10.1016/j.cca.2018.05.05529856976
   PubMed Web of Science ®Google Scholar
• Wade RG, Robinson AV, Lo MCI, et al. Baseline neutrophil–lymphocyte and platelet–lymphocyte ratios as biomarkers of survival in cutaneous melanoma: a multicenter cohort study. Ann Surg Oncol. 2018;25(11):3341–3349. doi:10.1245/s10434-018-6660-x30066226
   PubMed Web of Science ®Google Scholar
• Shirai Y, Shiba H, Haruki K, et al. Preoperative platelet–to–albumin ratio predicts prognosis of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Anticancer Res. 2017;37(2):787–794. doi:10.21873/anticanres.1137828179331
   PubMed Web of Science ®Google Scholar
• Saito N, Shirai Y, Horiuchi T, et al. Preoperative platelet to albumin ratio predicts outcome of patients with cholangiocarcinoma. Anticancer Res. 2018;38(2):987–992. doi:10.21873/anticanres.1231329374731
   PubMed Web of Science ®Google Scholar
• Leontovich AA, Dronca RS, Nevala WK, et al. Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients. Melanoma Res. 2017;27(1):32–42. doi:10.1097/CMR.000000000000029027824739
   PubMed Web of Science ®Google Scholar
• Guadagni S, Fiorentini G, Clementi M, et al. MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study. Melanoma Res. 2017;27(5):439–447. doi:10.1097/CMR.000000000000036728486243
   PubMed Web of Science ®Google Scholar
• Flaherty LE, Othus M, Atkins MB, et al. Southwest oncology group S0008: a phase III trial of high-dose interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma—an intergroup study of cancer and leukemia group B, children‘s oncology group, eastern cooperative oncology group, and southwest oncology group. J Clin Oncol. 2014;32(33):3771–3778. doi:10.1200/JCO.2013.53.159025332243
   PubMed Web of Science ®Google Scholar
• Eriksson H, Frohm-Nilsson M, Jaras J, et al. Prognostic factors in localized invasive primary cutaneous malignant melanoma: results of a large population-based study. Br J Dermatol. 2015;172(1):175–186. doi:10.1111/bjd.1317124910143
   PubMed Web of Science ®Google Scholar
• Maurichi A, Miceli R, Camerini T, et al. Prediction of survival in patients with thin melanoma: results from a multi-institution study. J Clin Oncol. 2014;32(23):2479–2485. doi:10.1200/JCO.2013.54.234025002727
   PubMed Web of Science ®Google Scholar
• Lyth J, Hansson J, Ingvar C, et al. Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark‘s level of invasion: results of a population-based study from the Swedish melanoma register. Br J Dermatol. 2013;168(4):779–786. doi:10.1111/bjd.1209523066913
   PubMed Web of Science ®Google Scholar
• Balch CM, Soong S, Gershenwald JE, et al. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013;20(12):3961–3968. doi:10.1245/s10434-013-3100-923838920
   PubMed Web of Science ®Google Scholar
• t Hout FEM, Haydu LE, Murali R, Bonenkamp JJ, Thompson JF, Scolyer RA. Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanoma. Ann Surg. 2012;255(6):1165–1170. doi:10.1097/SLA.0b013e31824c4b0b22566014
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong S, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28(14):2452–2459. doi:10.1200/JCO.2009.27.162720368546
   PubMed Web of Science ®Google Scholar
• Tesfamariam B. Involvement of platelets in tumor cell metastasis. Pharmacol Therapeut. 2016;157:112–119.
   PubMed Web of Science ®Google Scholar
• Moreau J, Pelletier F, Biichle S, et al. Increased levels of circulating platelet-derived microparticles are associated with metastatic cutaneous melanoma. Exp Dermatol. 2017;26(10):961–963. doi:10.1111/exd.1333928266752
   PubMed Web of Science ®Google Scholar
• Bauer AT, Suckau J, Frank K, et al. von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood. 2015;125(20):3153–3163. doi:10.1182/blood-2014-08-59568625977583
   PubMed Web of Science ®Google Scholar
• Becker KA, Beckmann N, Adams C, et al. Melanoma cell metastasis via P-selectin-mediated activation of acid sphingomyelinase in platelets. Clin Exp Metastasis. 2017;34(1):25–35. doi:10.1007/s10585-016-9826-627744579
   PubMed Web of Science ®Google Scholar
• Yin L, He J, Xue J, et al. PDGFR-β inhibitor slows tumor growth but increases metastasis in combined radiotherapy and Endostar therapy. Biomed Pharmacother. 2018;99:615–621. doi:10.1016/j.biopha.2018.01.09529653486
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Cui C, Zhou L, Lian B, et al. Safety and efficacy of apatinib combined with temozolomide in advanced melanoma patients after conventional treatment failure. Transl Oncol. 2018;11(5):1155–1159. doi:10.1016/j.tranon.2018.07.00930056366
   PubMed Web of Science ®Google Scholar
• Yang L, Zhu H, Luo P, Chen S, Xu Y, Wang C. Apatinib mesylate tablet in the treatment of advanced malignant melanoma. Onco Targets Ther. 2018;11:5333–5338. doi:10.2147/OTT.S17550730214239
   PubMed Web of Science ®Google Scholar
• Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315(15):1600–1609. doi:10.1001/jama.2016.405927092830
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532. doi:10.1056/NEJMoa150309325891173
   PubMed Web of Science ®Google Scholar